CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737

Experimental Hematology

Volumn 40, Issue 9, 2012, Pages

  Shimada, Kazuyuki ^a,b,c   Tomita, Akihiro ^b   Minami, Yosuke ^b   Abe, Akihiro ^b,d   Hind, Charlotte K ^c   Kiyoi, Hitoshi ^b   Cragg, Mark S ^c   Naoe, Tomoki ^b  

^a NAGOYA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ECTOPIC VIRAL INTEGRATION SITE 1 MDS1 TEL FUSION PROTEIN; HYBRID PROTEIN; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

EID: 84865006559     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.05.007     Document Type: Article

References (45)

1. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453.
2. Sawyers C.L., McLaughlin J., Witte O.N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995, 181:307-313.
3. Skorski T., Kanakaraj P., Nieborowska-Skorska M., et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86:726-736.
4. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
5. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
6. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
7. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
8. Horowitz M.M., Rowlings P.A., Passweg J.R. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996, 17(suppl 3):S5-S6.
9. Diamond J.M., Melo J.V. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011, 52(suppl 1):12-22.
10. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1018-1029.
11. Widmer N., Colombo S., Buclin T., Decosterd L.A. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003, 102:1142.
12. Mahon F.X., Belloc F., Lagarde V., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101:2368-2373.
13. Dai Y., Rahmani M., Corey S.J., Dent P., Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004, 279:34227-34239.
14. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
15. Holyoake T., Jiang X., Eaves C., Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064.
16. Holyoake T.L., Jiang X., Jorgensen H.G., et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001, 97:720-728.
17. Radich J.P. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program 2007, 384-391.
18. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., van Putten W.L., et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003, 101:837-845.
19. Mitani K., Ogawa S., Tanaka T., et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994, 13:504-510.
20. Ogawa S., Kurokawa M., Mitani K., Yazaki Y., Hirai H. Overexpression of Evi-1 and dysmegakaryopoiesis in human leukemias: reply to Carapeti, Goldman and Cross, Leukemia 1996;10:1561. Leukemia 1996, 10:1849.
21. Suzukawa K., Parganas E., Gajjar A., et al. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994, 84:2681-2688.
22. Nakamura Y., Nakazato H., Sato Y., Furusawa S., Mitani K. Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13). Am J Hematol 2002, 69:80-82.
23. Goyama S., Yamamoto G., Shimabe M., et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008, 3:207-220.
24. Kurokawa M., Mitani K., Irie K., et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998, 394:92-96.
25. Kurokawa M., Mitani K., Yamagata T., et al. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000, 19:2958-2968.
26. Tanaka T., Nishida J., Mitani K., Ogawa S., Yazaki Y., Hirai H. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 1994, 269:24020-24026.
27. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
28. Atsumi A., Tomita A., Kiyoi H., Naoe T. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 2006, 345:1471-1480.
29. Chan H.T., Hughes D., French R.R., et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003, 63:5480-5489.
30. Minami Y., Kiyoi H., Yamamoto Y., et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002, 16:1535-1540.
31. Cragg M.S., Howatt W.J., Bloodworth L., Anderson V.A., Morgan B.P., Glennie M.J. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ 2000, 7:48-58.
32. Hiraga J., Tomita A., Sugimoto T., et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009, 113:4885-4893.
33. Peeters P., Wlodarska I., Baens M., et al. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997, 57:564-569.
34. Kuroda J., Puthalakath H., Cragg M.S., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006, 103:14907-14912.
35. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
36. Yoshimi A., Goyama S., Watanabe-Okochi N., et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011, 117:3617-3628.
37. Cragg M.S., Harris C., Strasser A., Scott C.L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009, 9:321-326.
38. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009, 16:360-367.
39. Tse C., Shoemaker A.R., Adickes J., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421-3428.
40. Wilson W.H., O'Connor O.A., Czuczman M.S., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11:1149-1159.
41. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011, 29:909-916.
42. Bohlander S.K. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005, 15:162-174.
43. Goyama S., Kurokawa M. Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 2009, 100:990-995.
44. Hirai H., Sootome H., Nakatsuru Y., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9:1956-1967.
45. Paquette R.L., Nicoll J., Chalukya M., et al. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet 2011, 204:392-397.